Related Experiment Video
Updated: Apr 22, 2026
04:23
Application of Hemostatic Devices in Laparoscopic Hepatectomy
Published on: April 19, 2022
2.3K
Grave's Disease with Severe Hepatic Dysfunction: A Diagnostic and Therapeutic Challenge
Ashok Krishna Bhuyan1, Dipti Sarma1, Uma Kaimal Saikia1
1Gauhati Medical College, Guwahati 781032, India.
Case Reports in Medicine
|October 16, 2014
Summary
Thyrotoxicosis can cause liver dysfunction and neurological issues like Guillain-Barre syndrome. This case highlights the complexity of managing hyperthyroidism, especially when standard treatments fail, necessitating clear protocols.
Area of Science:
- Endocrinology
- Hepatology
- Neurology
Background:
- Hepatic dysfunction in thyrotoxicosis presents diagnostic challenges.
- Causes include hyperthyroidism itself, antithyroid drugs, or unrelated conditions.
- Neurological complications can mimic other serious disorders.
Purpose of the Study:
- To present a complex case of thyrotoxicosis with hepatic and neurological complications.
- To discuss diagnostic and therapeutic challenges in managing such cases.
- To emphasize the need for established treatment protocols.
Main Methods:
- Case report of a young female patient with thyrotoxicosis.
- Initial treatment with propylthiouracil.
- Subsequent management involved lithium, steroids, and methimazole.
- Neuropathy treated with intravenous steroids.
Main Results:
- Patient initially improved with propylthiouracil but later relapsed.
- Developed cholestatic and hepatocellular jaundice, sepsis, and paraplegia.
- Despite interventions, the patient's condition deteriorated.
- Treatment challenges included drug toxicity and sepsis.
Conclusions:
- Thyrotoxicosis management requires careful consideration of potential hepatic and neurological side effects.
- Established treatment protocols are crucial, especially where advanced therapies like radioiodine are unavailable.
- Prompt recognition and management of complications are vital for patient outcomes.
Related Concept Videos
01:28Graves' Disease I: Introduction
7
Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence...
7
01:24Graves Disease II: Pathophysiology
8
Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor,...
8
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
377
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
377
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
375
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
375
01:25Hyperthyroidism I: Introduction
7
Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
7
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
271
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271